# Study to Compare the Safety and Efficacy of UB-851 and Eprex®

> **NCT02708914** · PHASE3 · COMPLETED · sponsor: **UBI Pharma Inc.** · enrollment: 269 (actual)

## Conditions studied

- Renal Anemia

## Interventions

- **BIOLOGICAL:** UB-851
- **BIOLOGICAL:** Eprex

## Key facts

- **NCT ID:** NCT02708914
- **Lead sponsor:** UBI Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2021-10
- **Final completion:** 2021-10
- **Target enrollment:** 269 (ACTUAL)
- **Last updated:** 2023-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02708914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02708914, "Study to Compare the Safety and Efficacy of UB-851 and Eprex®". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02708914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*